Phase III studies on this drug to treat rare causes of obesity, such as POMC deficiency, leptin receptor mutation, Prader-Willi syndrome, Bardet-Biedl Syndrome, and Alström syndrome, are currently under way [155]. The gene discussed is POMC; the disease is Obesity.